Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC
CONCLUSION: These findings indicate that CeT not only induces ICD but also suppresses PD-L1 by down-regulating MAPK1 expression, which will provide an attractive strategy for ccRCC immunotherapy.PMID:38584553 | DOI:10.2174/0113816128288970240321073436 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 8, 2024 Category: Drugs & Pharmacology Authors: Hong-Fang Li Neng Zhu Jia-Jun Wu Ya-Ning Shi Jia Gu Li Qin Source Type: research
Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC
CONCLUSION: These findings indicate that CeT not only induces ICD but also suppresses PD-L1 by down-regulating MAPK1 expression, which will provide an attractive strategy for ccRCC immunotherapy.PMID:38584553 | DOI:10.2174/0113816128288970240321073436 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 8, 2024 Category: Drugs & Pharmacology Authors: Hong-Fang Li Neng Zhu Jia-Jun Wu Ya-Ning Shi Jia Gu Li Qin Source Type: research
Fumarate hydratase mutation associated uterine leiomyomas: A case report and literature review
Key Clinical MessageThe patient was found to have multiple uterine myomas at the age of 19, underwent laparoscopic myomectomy at the age of 20, and underwent laparotomic myomectomy again at the age of 23 due to the recurrence of uterine myoma. At the age of 25, the patient reappeared with symptoms and recurrence, and was diagnosed with uterine leiomyomas (ULMs) of FH mutation and high-grade squamous intraepithelial lesion (HSIL/CIN III) with gland involvement, after complete examination. Fumarate hydratase (FH) mutation screening is important when gynecologists encounter patients with early onset and multiple ULMs, it can ...
Source: Clinical Case Reports - April 8, 2024 Category: General Medicine Authors: Junyan Zhu,
Shanji Li,
Zhiguo Zhuang,
Hao Chen,
Chao Chen,
Jie Zhu Tags: CASE REPORT Source Type: research
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or predictive role of LIPI in metastatic renal cell carcinoma (mRCC) are still scarce. The aim of this study was to evaluate whether LIPI could be predictive of survival in mRCC patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 8, 2024 Category: Cancer & Oncology Authors: Luci ́a Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, Sylvie Negrier, Gwénaëlle Gravis, Robert J. Motzer, Christine Chevreau, Nizar M. Tannir, Stéphane Oudard, David F. McDermott, Brigitte Laguerre, Hans J. Hammers, Philippe Barthelemy, Elizabeth R. Tags: Original Research Source Type: research
Radiomics-based discriminant analysis of principal components to stratify the treatment response of lung metastases following stereotactic body radiation therapy
The lung is the second most common site for metastases for most solid tumor (such as primary lung cancer itself, colorectal, head and neck, renal cell and breast cancer), with 20 –54 % of cancer patients developing lung metastases during their disease [1]. If patients with aggressive metastatic dissemination are usually treated with systemic therapy, patients with a modest metastatic burden, also known as oligometastatic disease, are more likely to benefit from local trea tment [2]. Stereotactic body radiation therapy (SBRT) is a potentially effective alternative treatment modality that is now regarded as being equally ...
Source: Physica Medica: European Journal of Medical Physics - April 8, 2024 Category: General Medicine Authors: Savino Cilla, Francesco Deodato, Carmela Romano, Gabriella Macchia, Milly Buwenge, Alessio G. Morganti Tags: Original paper Source Type: research
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
We report that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed RCC xenograft tumors. We also report results from 16 patients with relapsed/refractory ccRCC who received CTX130 in a phase I, multicenter, first-in-human clinical trial. No patients encountered dose-limiting toxicity, and disease control was achieved in 81.3% of patients. One patient remains in a durable complete response at 3 years. Finally, we report on a next-generation CAR T construct, CTX131, in which synergistic potency edits to CTX130 confer improved expansion and efficacy in preclinical studies. Thes...
Source: Cancer Control - April 7, 2024 Category: Cancer & Oncology Authors: Sumanta K Pal Ben Tran John B A G Haanen Michael E Hurwitz Adrian Sacher Nizar M Tannir Lihua E Budde Simon J Harrison Sebastian Klobuch Sagar S Patel Luis Meza Mary-Lee Dequeant Anna Ma Qiuling Ally He Leah M Williams Alissa Keegan Ellen B Gurary Henia D Source Type: research
Ginsenoside Rh4 Facilitates the Sensitivity of Renal Cell Carcinoma to Ferroptosis via the NRF2 Pathway
CONCLUSIONS: Rh4 made RCC cells more sensitive to ferroptosis by inhibiting the NRF2 signaling and suppressing the expression of antioxidant enzymes. Therefore, combining Rh4 with ferroptosis-inducing reagents to treat RCC had potential therapeutic application.PMID:38583003 | DOI:10.56434/j.arch.esp.urol.20247702.16 (Source: Archivos Espanoles de Urologia)
Source: Archivos Espanoles de Urologia - April 7, 2024 Category: Urology & Nephrology Authors: Huandong Zhao Ruimin Ding Jiarui Han Source Type: research
